-
Baylor Genetics Presents New Data on Genetic and Functional Testing to Diagnose Mitochondrial Disorders at 2025 ACMG Annual Clinical Genetics Meeting
Mar 23, 2025
-
Anthos Therapeutics, Inc., a business that produces abelacimab (full human monoclonal antibody), a late-stage medication being developed to prevent stroke and systemic embolism in patients with atrial fibrillation, has agreed to be acquired by Novartis. Upon concluding the deal, Novartis will pay $925 million upfront, subject to certain usual adjustments. If certain sales and regulatory milestones are met, Novartis may also pay an additional $2.15 billion.
Mar 23, 2025
-
Coronado Research has appointed Gary Lyons as EVP Medical Affairs. Gary is a seasoned senior Medical Affairs leader with extensive strategic and operational implementation experience across the industry and product lifecycle.
Mar 19, 2025
-
Funding led by global software investor Insight Partners comes as the surge in cancer cases compounds the impact of the shrinking pathologist workforce.
Mar 18, 2025
-
Diasorin announced the availability of its Simplexa C. Auris Direct kit in all countries accepting the CE mark. The targeted molecular diagnostic test is performed on the LIAISON MDX instrument, yielding patient results in less than two hours.
Mar 17, 2025
-
Mar 17, 2025
-
START's site network solidifies its global leadership in urological cancer trials.
Mar 17, 2025
-
As Baylor Genetics celebrates a decade of leadership at the forefront of genetic testing, it is set to exhibit its latest scientific studies in genetic testing at the 2025 ACMG Annual Clinical Genetics Meeting, taking place March 18-22, 2025, in Los Angeles, CA. The Company will be located at Booth #217 at the Los Angeles Convention Center.
Mar 12, 2025
-
Coronado Research has appointed Nick Littlebury as EVP, Regulatory Affairs. Nick is a senior regulatory leader with extensive strategic and operational experience across the pharmaceutical industry's product lifecycle.
Mar 12, 2025
-
Mar 11, 2025
-
ClearNote Health announced an agreement with Claritev, Inc., (previously MultiPlan, Inc.) that will make ClearNote Health’s Avantect Pancreatic Cancer Test available to health plan members accessing Claritev’s national PHCS and MultiPlan Networks.
Mar 11, 2025
-
Augurex has received UK Conformity Assessed marking for JOINTstat®, authorizing its use in Great Britain for rheumatoid arthritis diagnosis and management. JOINTstat® is a well-established rheumatoid arthritis blood test in North America, approved by Health Canada and available in the U.S. as a laboratory-developed test.
Mar 9, 2025
-
Mural Health Technologies, Inc., a patient-first clinical trial technology company, and ICON plc (NASDAQ: ICLR), a global healthcare intelligence and clinical research organization, today announce a partnership to utilize the participant management and payments platform, Mural Link.
Mar 3, 2025
-
IQVIA Laboratories is introducing its Site Lab Navigator, an advanced suite of solutions that automates and streamlines lab workflows for clinical trial sponsors and investigator sites, aiming to significantly reduce administrative burden on sites and improve the quality and execution of trials.
Mar 3, 2025
-
Owkin, a pioneer in Agentic AI for decoding the complexities of biology, has launched a comprehensive multimodal patient data discovery program to accelerate multimodal data access and advance medical research.
Feb 26, 2025
-
ClearNote Health announced New York State has approved its Avantect Pancreatic Cancer Test. The ClearNote Health Laboratory now has its NYSDOH permit, as well as its CLIA certification and CAP accreditation.
Feb 17, 2025
-
Feb 18, 2025
-
CluePoints, provider of leading statistical and AI-driven software solutions, has been shortlisted for “Team Excellence in the Management of Clinical Data” at the 2025 ACDM Awards.
Feb 17, 2025
-
Phastar, a global specialist biometrics & data science contract research organization (CRO), won a Best of Show Award at Summit for Clinical Ops Executives (SCOPE) US 2025.
Feb 12, 2025
-
Feb 12, 2025